Board of Directors
Wayne Channon Chairman Wayne Channon is a successful entrepreneur with experience of managing high growth companies from start-up to exit. He has run companies in both Europe and the US. Wayne currently also chairs Cells4Life, a leader in the UK umbilical cord blood stem cell storage market. Amongst his companies, he founded ilion group plc which grew to be Europe’s second largest networking distributions group with revenues of €500million, operating in nine countries. ilion was subsequently floated on the Official List of the London Stock Exchange. Wayne graduated from Imperial College in mathematical physics and joined IBM in sales and marketing.
Dr Barbara Domayne-Hayman Chief Executive Officer Dr Barbara Domayne-Hayman joined Stabilitech as CEO in October 2007. Barbara is a chemist by training and after obtaining her first degree at Oxford University, UK, stayed on to complete a D Phil on penicillin biosynthesis with Sir Jack Baldwin. She then left research and joined ICI/Zeneca Agrochemicals where she worked for nearly eleven years, in a variety of international roles of increasing seniority in sales and marketing, business development, product management and commercial strategy. A period in management consulting in Ernst & Young Strategy Group was followed by the Sloan Fellowship programme at London Business School. Barbara then joined Celltech (now UCB) as Senior Business Development Manager. After two years she was appointed Commercial Director at Arrow Therapeutics, where she worked for over four years. Arrow was acquired by AstraZeneca in February 2007 for $150 million.
Dr Jeff Drew Chief Scientific Officer Dr Jeff Drew is the founder of the Stabilitech and the developer of the company’s proprietary technology. Jeff holds a degree in Microbiology and Virology from Manchester University, and a PhD in Molecular Virology from Reading University Institute of Animal Health at Pirbright, UK. Jeff has 18 years experience in microbiological, cancer, gene therapy and genetic research. His research has been conducted within various research institutes and departments at the UK including the Exotic Virus Research Laboratories at the Institute of Animal Health, Universities of Oxford, London, the Marie Curie Research Institute and the Chester Beatty Laboratories at the Institute of Cancer Research. He is the co-founder and a non-executive director of Cells4Life, a leading UK umbilical cord blood stem cell storage company.
Dr Peter Cozens Non-Executive Director Dr. Peter Cozens has worked for more than 30 years in the pharmaceutical industry, with broad international experience in both the biotechnology and conventional pharmaceutical sectors of the industry. In 1991 he joined Medeva PLC where he became Executive Vice President, Business Development and Intellectual Property, responsible for the building of Medeva’s development pipeline, managing its patents and trademark function and overseeing multinational patent litigation. Prior to Medeva he worked as a research scientist for Ciba-Geigy (now Novartis) and in R&D and business development at Wellcome (now GSK). He is currently a Partner at the consulting firm, ProPharma Partners Ltd., a member and former Chairman of the Intellectual Property Advisory Committee of the UK BioIndustry Association, a non-executive Director of Eden BioPharma Limited and non-executive chairman of Zysis Ltd.
